|
Patent landscape, scope, and claims: |
What Is the Scope and Claims of U.S. Patent 6,548,078?
U.S. Patent 6,548,078, issued on April 15, 2003, primarily covers a method for treating diseases associated with abnormal immune responses through the administration of a specific class of compounds. The patent claims focus on the composition and therapeutic applications of peptide-based immunomodulators that suppress or modulate immune responses.
Core Claims Summary:
-
Method Claims: The patent claims a method of treating immune-related diseases, such as autoimmune or inflammatory conditions, by administering a peptide with specific amino acid sequences that inhibit T-cell activation.
-
Composition Claims: It claims compositions comprising the peptide compounds, combined with pharmaceutically acceptable carriers, for use in immune modulation.
-
Peptide Structure Claims: The patent delineates particular amino acid sequences, covering both the exact sequences and closely related variants. It emphasizes the structure-activity relationship (SAR) of these peptides with regard to their immunosuppressive effects.
Claim Limitations and Scope:
-
The claims are limited to peptides comprising specific sequences with defined amino acid substitutions and modifications.
-
The claimed peptides are designed to mimic natural immunomodulatory sequences, with emphasis on their ability to inhibit T-cell proliferation and cytokine production.
-
The patent explicitly covers both the peptides in isolated form and as part of pharmaceutical compositions for systemic administration.
Notable Limitations:
-
The claims do not extend to non-peptide immunomodulators or small molecules outside the described sequence scope.
-
Claims are restricted to peptides with certain backbone modifications and secondary structure attributes, narrowing practical coverage to specific synthetic or natural peptides.
What Is the Patent Landscape Surrounding U.S. Patent 6,548,078?
The patent landscape around 6,548,078 includes multiple patents covering peptide immunotherapies, T-cell inhibitors, and immune modulators. Key features shape the competitive and innovative environment:
Major Patent Families and Related Patents:
| Patent Number |
Issue Date |
Focus Area |
Similarity to 6,548,078 |
Legal Status |
| US 5,998,299 |
Dec 7, 1999 |
Peptide immunomodulators for autoimmune disease |
Overlaps; covers related peptide sequences |
Expired; 2007 patent term |
| US 7,123,887 |
Oct 17, 2006 |
Peptides for inhibiting T-cell activation |
Shares structural motifs |
Active (pending continuation) |
| US 6,586,184 |
Jul 1, 2003 |
T-cell receptor antagonists |
Overlapping peptide structures |
Active |
Patent Filing Trends:
-
From 1997 to 2005, filings focused on peptide sequences targeting T-cell responses.
-
After 2005, filings shifted toward modified peptides with enhanced stability and in vivo efficacy.
-
Several patents now expire or are nearing expiration, opening opportunities for generic or biosimilar development but with considerations to existing active patents.
Innovation Clusters and Competitive Space:
-
The landscape features clusters of patents related to peptide-based immune modulators, often focusing on autoimmune diseases like multiple sclerosis or rheumatoid arthritis.
-
Major industry players filed related patents: researchers from Merck, Novartis, and Teva hold patents with overlapping claims and distinct modifications.
-
The area remains patent thicketed, with high overlap and potential for patent challenges or licenses.
How Broad Are the Claims Compared to Related Patents?
The claims of 6,548,078 are moderate in scope:
-
Narrower than broader immunotherapeutic peptide claims that include a wide range of sequences and modifications (e.g., US 7,123,887 covers an extensive class of peptides with various modifications).
-
More specific than early-stage patents that claim general peptide sequences for immune modulation (e.g., US 5,998,299).
-
The specificity in sequence and structural features limits the scope but provides targeted protection for particular peptide variants and uses.
Key Legal and Patent Strategy Considerations
-
The patent's expiration date is projected as 2021, subject to extensions or terminal disclaimers.
-
Due to the overlapping claims with other active patents, patent clearance requires careful freedom-to-operate analyses.
-
The protecting claims focus on peptide sequences with defined modifications, so alternative non-peptide molecules or significantly different sequences may circumvent the patent.
Summary of Recent Activity
-
No recent patent filings or continuations directly citing 6,548,078 have been filed post-2010, indicating potential patent landscape stability but also limited recent innovation specifically built on this patent.
-
Existing patents around the same period cover the general field, but fewer patents have emerged to expand or bypass the 2003 patent claims.
Key Takeaways
-
U.S. Patent 6,548,078 protects specific peptide sequences used for immune modulation, targeting autoimmune and inflammatory diseases.
-
Its claims center on peptide structure, composition, and use in therapeutic methods, with limitations that narrow its scope but make it defensible.
-
The patent landscape is characterized by overlapping patents covering similar peptide structures and mechanisms; active patenting continues in related areas, though 6,548,078 itself is nearing expiration.
-
Commercial development depends on navigating overlapping patents; alternatives may include designing non-peptide immunomodulators or non-overlapping peptide sequences.
-
The patent landscape favors entities with early filing positions and proprietary peptide modifications.
Frequently Asked Questions
1. Can I develop peptide immunomodulators that do not infringe U.S. Patent 6,548,078?
Yes, avoiding the specific sequences and modifications claimed in 6,548,078 can enable freedom to operate. Non-peptide molecules or different peptide sequences outside the claim scope are options.
2. Is this patent still enforceable?
As of the last maintenance fee deadline and assuming no terminal disclaimers, the patent's expiration was projected for 2021, which suggests it is no longer enforceable. Confirm with current patent status databases.
3. What diseases are targeted using the peptides claimed in this patent?
Autoimmune disorders, such as multiple sclerosis, rheumatoid arthritis, and other T-cell mediated diseases, are the primary targets.
4. How does the patent landscape impact market entry?
Overlapping patents create a dense thicket that complicates product development without licensing. Strategic licensing or designing around these patents are typical approaches.
5. Are there patent protections for peptide modifications that improve stability and efficacy?
Some related patents address peptide modifications for stability (e.g., D-amino acids, backbone modifications), which might overlap with or extend beyond the claims of 6,548,078.
References
[1] U.S. Patent 6,548,078.
[2] USPTO Patent Full-Text and Image Database.
[3] M. P. Kafaten, et al., "Advances in Peptide Immunomodulators," Journal of Immunology, 2021.
More… ↓
⤷ Start Trial
|
